C8 MediSensors Closes $19 million Preferred Stock Financing
2 Pages
English
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

C8 MediSensors Closes $19 million Preferred Stock Financing

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer
2 Pages
English

Description

C8 MediSensors Closes $19 million Preferred Stock Financing PR Newswire SAN JOSE, California, June 12, 2012 - Plans to Introduce Optical Glucose Monitor in Europe in 2012 SAN JOSE, California, June 12, 2012 /PRNewswire/ -- C8 MediSensors, Inc. (www.c8medisensors.

Subjects

Informations

Published by
Reads 11
Language English

Exrait

C8 MediSensors Closes $19 million Preferred
Stock Financing
PR Newswire
SAN JOSE, California, June 12, 2012
- Plans to Introduce Optical Glucose Monitor in
Europe
in 2012
SAN JOSE, California
,
June 12, 2012
/PRNewswire/ -- C8 MediSensors, Inc.
(www.c8medisensors.com), the leading company developing noninvasive
continuous glucose monitoring for people with diabetes, announced today that
it has raised an incremental
$19 million
through the sale of Preferred C-1 stock.
This additional round of funding helps C8 MediSensors prepare for its upcoming
product launch in
Europe
. C8 MediSensors' leading investors participated in this
funding round.
Nearly 300 million people worldwide suffer from diabetes. C8 MediSensors has
pioneered the use of light, specifically Raman spectroscopy, to measure
glucose non-invasively with a continuous glucose monitor that is worn around
the abdomen and sends readings to the user's smartphone.
C8 MediSensors' CEO, Paul Zygielbaum, himself a person with diabetes,
commented: "Better diabetes management requires better glucose visibility to
the patient. You can't control what you can't see. After years of research,
development and clinical testing, we are thrilled to be on the verge of
introducing our optical glucose monitor, which is designed to provide people
like me with continuous visibility into their glucose levels throughout the day."
C8 MediSensors has filed for CE Mark approval and plans to introduce their
optical continuous glucose monitor in
Europe
in 2H 2012, pending regulatory
approval.
About C8 MediSensors
Headquartered in
San Jose CA
, C8 MediSensors' breakthrough patent-protected
technology is being developed to give people with diabetes an adjunctive,
continuous view of their glucose levels.
Visit www.c8medisensors.com.
This document contains forward-looking statements. Any statements contained
in this document that are not statements of historical fact may be deemed to
be forward- looking statements, including, without limitation, statements
relating to C8 MediSensors' anticipated product sales and financing needs.
These forward-looking statements are based upon C8 MediSensors' current
expectations. Actual results could differ materially from these forward-looking
statements as a result of certain factors, including, without limitation, risks
associated with market conditions, customer demand for the product, and risks
and uncertainties associated with C8 MediSensors' business and finances in
general. You are cautioned not to place undue reliance on these forward-
looking statements, which speak only as of the date of this document. C8
MediSensors does not undertake any obligation to update any forward-looking
statements as a result of new information, future events, changed assumptions
or otherwise.
C8 MediSensors, Inc. 6375 San Ignacio Avenue,
San Jose, CA
95119,
USA
www.C8MediSensors.com